Who is sponsoring NCT03919617?

NCT03919617 is sponsored by University of California, San Diego.

What condition does NCT03919617 study?

NCT03919617 studies Type 1 Diabetes Mellitus.

What is the status of NCT03919617?

NCT03919617 is currently COMPLETED.

Last reviewed 2022-07-15 · How we verify

Metabolic Pathways of GRA in Patients With Type 1 Diabetes

NCT03919617 PHASE1, PHASE2 COMPLETED

A pilot study for individuals with Type 1 Diabetes who are willing to add a GRA (Glucagon Receptor Antagonist) to their current Diabetes treatment regimen. There will be 10 study visits over the course of approximately 8 weeks, with 4 weeks of once weekly, subcutaneous GRA (REMD-477) injection. Testing includes 2 MRI scans, 2 glucose challenges, and 2 insulin withdrawal challenges along with physical assessments and vitals.

Details

Lead sponsor	University of California, San Diego
Phase	PHASE1, PHASE2
Status	COMPLETED
Enrolment	4
Start date	Mon Jul 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue May 31 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Type 1 Diabetes Mellitus

Interventions

REMD-477

Countries

United States